Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis

Proactive - Interviews for investors

Lisata Therapeutics Executive Vice President and Chief Medical Officer Dr. Kristen Buck joined Steve Darling from Proactive to announce a new research agreement with the University of Cincinnati to explore Lisata’s novel cyclic peptide, certepetide, combined with bevacizumab, for treating endometriosis. Bevacizumab has shown effectiveness against endometriosis, yet its high dosages lead to systemic side effects, limiting its suitability for young, otherwise healthy women. Under this agreement, the University of Cincinnati will conduct the research while Lisata provides funding and supplies of certepetide. Lisata hopes this combination will offer a targeted, effective solution for endometriosis—a painful condition affecting 6.5 million U.S. women, often leading to severe pain, infertility, and other health complications. #proactiveinvestors #lisatatherapeuitcsinc #nasdaq #lsta #endometriosis #certepetide #Certepetide #EndometriosisTreatment #UniversityofCincinnati #WomensHealth #MedicalResearch #Biotechnology #Integrins #Neuropilin #ProactiveInterview #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews